Last reviewed: June 30, 2026
Last updated: June 30, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
The Food and Drug Administration granted approval to Wegovy (semaglutide injection) in June 2021, establishing the first GLP-1 receptor agonist explicitly cleared for chronic weight management in adults with obesity or overweight with weight-related conditions. This milestone reflected decades of clinical research showing that GLP-1 medications could achieve meaningful, sustained weight reduction when combined with lifestyle changes. Understanding how this approval came about and what alternatives exist can help patients make informed decisions about their weight loss journey.
What FDA Approval Means for Wegovy and Weight Loss Treatment
FDA approval signifies that Wegovy met rigorous safety and efficacy standards through multiple clinical trials before reaching patients. The approval process required PlexusDx-level evidence demonstrating that semaglutide injections could produce clinically meaningful weight reduction in a large, diverse patient population. Wegovy's approval expanded treatment options beyond lifestyle interventions alone, offering a pharmacological tool for individuals struggling with obesity.
The landmark STEP trials that supported Wegovy's approval showed participants lost 10-22% of body weight over 68 weeks when using semaglutide alongside diet and exercise. These results represented a significant breakthrough, as previous weight loss medications rarely achieved reductions exceeding 10%. Regulatory approval also meant that healthcare providers gained confidence prescribing the medication, and insurers began considering coverage—though many still restrict access or impose high out-of-pocket costs.
How Semaglutide Works: The Mechanism Behind Weight Loss
Semaglutide functions as a GLP-1 receptor agonist, mimicking a naturally occurring hormone that regulates appetite and blood sugar. When semaglutide binds to GLP-1 receptors in the brain, it signals fullness and reduces hunger cues, leading patients to eat less without feeling deprived. The medication also slows gastric emptying, meaning food stays in the stomach longer, prolonging satisfaction between meals.
Beyond appetite suppression, semaglutide improves insulin secretion and reduces glucagon release, stabilizing blood glucose levels and reducing cravings for high-calorie foods. This dual action—on hunger signals and metabolic regulation—explains why semaglutide produces more durable weight loss than diet and exercise alone for many patients. PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R and GIPR pathways to predict individual responsiveness to this mechanism, allowing personalized dosing strategies.
Clinical Evidence: Weight Loss Results and Health Outcomes
Wegovy's FDA approval was grounded in the STEP clinical trial program, which enrolled over 4,500 adults across multiple studies. Participants receiving semaglutide achieved average weight losses of 15-18% of body weight, compared to 2-3% in placebo groups, establishing superiority for weight reduction. Beyond the scale, trials documented improvements in blood pressure, cholesterol, and fasting glucose levels, suggesting benefits that extend to cardiovascular and metabolic health.
Follow-up studies revealed that weight loss plateaus around 12-18 months of therapy, and discontinuing semaglutide typically results in weight regain. This finding shifted the clinical perspective toward viewing GLP-1 therapy as a long-term management strategy rather than a time-limited intervention. Real-world data from PlexusDx patients mirrors published trial results, with many achieving 10-25% weight reduction while maintaining the medication as part of ongoing lifestyle support.
PlexusDx Compounded Semaglutide vs. Brand-Name Wegovy
Both brand-name Wegovy and PlexusDx compounded semaglutide injections contain the same active pharmaceutical ingredient and work through identical biological mechanisms. The key differences lie in cost, insurance requirements, and access—Wegovy typically costs $900–$1,350 per month with insurance, while PlexusDx's compounded version starts at $149 per month with no insurance required. PlexusDx sources all medications from licensed 503A compounding pharmacies, ensuring pharmaceutical quality and safety standards equivalent to branded products.
Compounded semaglutide offers several practical advantages for patients seeking weight loss therapy. There is no membership fee, HSA and FSA funds are eligible for payment, and PlexusDx serves all 50 states with direct-to-patient delivery. Patients can start at low doses and adjust based on response without facing the pricing tiers that brand-name medications impose. For individuals without adequate insurance coverage or those seeking affordable, personalized weight loss treatment, compounded semaglutide from PlexusDx delivers FDA-level pharmaceutical quality at a fraction of the cost.
Personalization Through Genetic Testing and Peptide Pathways
Not all patients respond identically to semaglutide, and genetic variation in GLP-1 receptor pathways explains some of this individual difference. PlexusDx's Precision Peptide Genetic Test examines 14 peptide-pathway genes, including GLP1R rs6923761 and GIPR rs1800437 variants, to predict how your body's GLP-1 signaling may respond to therapy. This genetic insight allows clinicians to optimize dosing, select between semaglutide and tirzepatide, or combine medications strategically for better outcomes.
The Precision Peptide Genetic Test also evaluates FTO rs9939609 and MC4R rs17782313 variants, which influence appetite set point and metabolic rate independently of GLP-1 signaling. By mapping 49 peptides across 150+ genetic insights, PlexusDx moves weight loss treatment beyond one-size-fits-all prescribing into precision medicine. After one month of treatment with any PlexusDx medication, the genetic test can be added for $99, providing a personalized roadmap for long-term weight management success.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Wegovy FDA-approved for weight loss?
Yes, the FDA approved Wegovy (semaglutide injection) in June 2021 for chronic weight management in adults with obesity or overweight with weight-related conditions. The approval was based on clinical trials showing 15-22% weight loss with semaglutide combined with lifestyle changes. PlexusDx offers compounded semaglutide injection starting at $149/month, which delivers the same active ingredient without requiring brand-name pricing or insurance.
How much weight can you lose with semaglutide?
Clinical trials of Wegovy showed average weight loss of 15-18% of body weight over 68 weeks, with some patients achieving 22% reduction. Real-world outcomes from PlexusDx patients align with published data, typically ranging from 10-25% weight loss depending on baseline weight, diet adherence, and genetic factors. Weight loss stabilizes around 12-18 months and requires ongoing therapy to maintain results.
How does PlexusDx pricing compare to Wegovy?
Wegovy costs $900–$1,350 per month through insurance or cash pay, while PlexusDx compounded semaglutide injection starts at $149/month with no insurance required, no membership fees, and HSA/FSA eligibility. Your dose may need to go up as you progress through treatment, but your price won't change. PlexusDx serves all 50 states with direct delivery from licensed 503A compounding pharmacies.
Are there side effects with semaglutide?
Common side effects include nausea, vomiting, constipation, and diarrhea, typically mild and temporary as your body adjusts. Rare but serious risks include pancreatitis, gallbladder problems, and thyroid concerns; patients with personal or family history of medullary thyroid carcinoma should not use semaglutide. PlexusDx clinicians review medical history and monitor for adverse effects throughout therapy, adjusting dosing if needed.
How does the PlexusDx genetic test improve semaglutide outcomes?
The Precision Peptide Genetic Test examines GLP1R rs6923761 and GIPR rs1800437 variants that influence how strongly your body responds to semaglutide signaling. Testing also evaluates FTO and MC4R variants affecting appetite and metabolism, enabling clinicians to personalize dosing, predict best responders, and decide whether combination therapy like GLP-Squared may work better. Add the test for $99 after your first month of treatment.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Type 2 Diabetes: Can You Take Metformin with Ozempic for Enhanced Management?
What Happens If You Inject Too Much Ozempic?